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Well woman screening is an accepted part of general 
practice services. Checks are carried out by health 
professionals including general practitioners and 
practice nurses. Screening may involve one or more 
of the following components: blood pressure, weight 
measurement, cholesterol and glucose levels, breast 
examination, cervical smear and vaginal examination. 
The evidence base for such screening tests varies; in 
particular routine breast examination and bimanual 
vaginal examination of asymptomatic women do not 
appear to fulfil the necessary criteria for adoption 
of these strategies as screening tests. The Wilson 
criteria for screening state that a screening test should 
accurately identify a high proportion of patients with 
early disease.1 This article looks at the evidence for CBE 
of asymptomatic women: screening CBE as opposed to 
diagnostic CBE.
Thirty years ago Frame and Carlson critically reviewed all 
screening tests offered to patients as periodic (usually 
annual) health checks. They recommended that only health 
screening shown to be of proven effectiveness should be 
performed. They stated that there was insufficient evidence 
to recommend a clinician’s breast examination to screen 
for breast cancer.2 In 1993 Carney et al3 highlighted how 
what constitutes a ‘check up’ varies between doctors, and 
between doctors and patients. In the study, 59 primary 
care physicians reviewed asymptomatic 55 year old women 
requesting ‘check ups’. Of note, 65% of physicians provided 
a clinical breast examination (CBE) and another 20% did so 
only when prompted by the patient. While not all GPs may 
offer CBE opportunistically, many will perform CBE at the 
request of the patient. Do patients fully understand the 
significance of being told that the examination is ‘normal’ 
or that ‘no abnormalities have been found’?
Case example
Mary B, 42 years of age, requests a well woman check. She says she would like a breast 
examination. There is no family history of breast cancer and she is not aware of any breast 
problems. At the practice meeting the nurse asks whether clinical breast examination (CBE) 
should form part of the check and what, if any, information she should give women before 
performing what she feels is a screening test.
BACKGROUND 
Clinical breast examination (CBE) is often offered as a component of the well woman check or carried out at the request 
of an asymptomatic woman. In these cases the examination is a screening procedure, as opposed to a diagnostic CBE 
in a symptomatic woman. 
OBJECTIVE 
This article examines the evidence for screening CBE.
DISCUSSION 
Screening CBE should involve informed consent. A negative examination does not exclude the presence of breast 
cancer and women should be aware of this. There have been no randomised controlled trials of CBE alone, only trials 
comparing CBE with mammography for the detection of breast cancer. While there is a low sensitivity (54%) for CBE, 
the specificity is high (94%). It is unlikely that these figures are discussed with patients. There are different methods of 
CBE, and these are described in the literature without a firm evidence base as to effectiveness. However, evidence does 
suggest that practice on models and retraining help improve clinicians’ skills.
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Literature review 
We searched MEDLINE, Google and the 
Cochrane database using the terms ‘clinical 
breast examination’,  ‘breast screening’ 
and ‘breast examination’. We also examined 
textbooks. Many papers dealt only with 
mammography. Many recent American papers 
drew heavily from a 1999 paper by Barton et 
al.4 This is not a systematic review: a Cochrane 
review of 2003 found no randomised trials of 
clinical breast examination.5
 A ‘normal’ CBE does not rule out disease, 
but certain abnormal findings greatly increase 
the probability of breast cancer. Screening 
mammography combined with CBE appears to 
give better results.4 Clinical breast examination 
alone has never been compared in a clinical trial 
with no screening; only with mammography.6 A 
comparison of CBE with no screening is unlikely 
to happen now on ethical grounds, yet this 
would provide evidence for the usefulness or 
not of CBE in countries where regular screening 
mammography is unavailable or too expensive 
for the general population. As mammography 
is only recommended in perimenopausal or 
postmenopausal women, the effectiveness of 
CBE alone in younger women also needs to 
be explored, although in this age group the 
incidence of disease is much lower: 75% of 
cases of breast cancer develop in women 50 
years of age and over. However, in younger 
women breast cancers are likely to be larger 
and more aggressive than in older women.6 
 Clinical examination textbooks disagree as to 
when a breast examination should be performed. 
Talley and O’Connor state that: ‘breast examination 
is a vitally important part of the general physical 
examination’.7 Macleod implies that breast 
examination is for symptomatic women only.8 A 
recent Australian textbook on women’s health 
advises examination of the breasts from the age 
of 40 years by a clinician because, while CBE 
only detects 50% of breast cancers present and 
screening mammography detects 90%, it is 
possible that CBE may pick up some of the 10% 
not detected by mammography.9 However, this 
advice is contrary to a general practice guide to 
women’s health that states that further research 
is required before CBE can be recommended 
as a screening tool.10 Such research should be 
a ‘randomised controlled trial comparing clinical 
breast examination with no screening at all’.10 
This recommendation is based on the results 
of the Canadian Breast Screening Study that 
compared screening via mammography and CBE 
with screening via CBE alone. After 13 years 
follow up there was no statistical difference in 
the pickup rates of breast cancer or of mortality 
between the two groups.11 However, this study 
suggested that CBE is more sensitive in women 
aged 40–49 years than older women; in contrast 
to mammography. Most screening guidelines 
therefore synthesise the research either with 
a recommendation that CBE complements 
mammography12 or they do not recommend CBE 
at all. For example the recommendations of The 
Royal Australian College of General Practitioners 
(RACGP) do not include breast examination as 
a routine screening procedure. Note is made 
that CBE has not been shown to reduce breast 
cancer mortality but is recommended in women 
who are at increased risk, in conjunction with 
mammography.13 Routine breast examination is 
also stated not to be indicated in asymptomatic 
women starting hormonal contraception or 
during use,14 although many GPs will remember 
being advised to do this in the past, and an 
American text from 2002 recommends a breast 
examination for adolescent girls before starting 
the combined oral contraceptive pill.15 However, 
it is important to understand in greater depth 
the use and limitations of CBE as a screening 
tool, particularly for those women who decline 
or cannot undergo mammography, and for those 
patients who request CBE. 
Screening for breast cancer
When considering the nature of screening tests 
for breast cancer, there are important areas to 
explore (Table 1). With breast screening, the 
clinician is aiming to pick up early cancers that 
will need to be surgically removed in combination 
with possible radiotherapy and chemotherapy. In 
the early stages of the disease, treatment is 
likely to be more effective and women have 
more options. The rationale behind the screening 
is that larger tumours have a poorer prognosis 
than smaller tumours.16 However, the potential 
for cure is much less than in the cervical smear 
program. Women used to having cervical 
smears taken regularly may not understand the 
difference between the two screening tests 
unless adequately counselled. 
 With breast cancer screening, the total 
preclinical phase (TPCP) must be taken into 
account. This is the period from when the cancer 
first starts until it is detected by symptoms. The 
detectable preclinical phase (DPCP), part of the 
TPCP, is the period during which the cancer is 
detected by screening in asymptomatic patients. 
The ideal screening test is one that detects 
a cancer early in the DPCP and which can be 
followed by treatment to reduce mortality. 
Mammography screening is associated with 
a longer DPCP than CBE.17 However, picking 
up breast cancer early may not reduce overall 
mortality but rather increase the time that a 
woman lives with the diagnosis. ‘As screening 
advances the time of cancer diagnosis survival 
rates will appear to improve, even if screening 
does nothing to delay the time of death.’17 
 We have known for many years that breast 
screening tends to detect cancers that are 
relatively slow growing and are biologically more 
favourable18 with a longer DPCP. Faster growing 
and more malignant cancers are more likely to 
occur within screening intervals, being detected 
by women themselves. 
The effectiveness of screening 
Before mammography was widely available, 
CBE did pick up breast cancers, however there 
is no evidence that this reduced mortality from 
the disease compared to women presenting 
with breast symptoms. Barton et al4 carried 
out a systematic review of CBE in 1999. 
They list 110 references spanning the years 
1967–1999. As early as 1975, researchers were 
querying the validity of clinical examination and 
mammography as screening tests.19 The data 
synthesis in the Barton review raises questions 
about the studies reported and the authors 
address these in their article. From the studies 
CBE was found to detect between 3 and 
45% of breast cancers missed by screening 
mammography. Barton et al feel that some of 
the discrepancy in these results may be due 
to a lack of clarity as to what type of CBE was 
carried out, as this is rarely mentioned in the 
research findings: there is a ‘lack of consistent 
and standardised examination techniques’.4 
However, we must also question the reliability 
of the mammography and ask whether these 
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results would be the same today. The conclusion 
from this review is that there is indirect 
evidence supporting the effectiveness of CBE 
as a screening tool. 
 McDonald et al20 published a literature 
review in 2004, but specifically state that they 
were only looking at the contribution of CBE 
to screening rather than its effectiveness in 
reducing breast cancer mortality. Their review 
of more recent literature (2000–2003) than the 
Barton paper quotes three studies showing that 
4.6–5.7% of cancers were identified solely by 
CBE, while another study from 2003 gives a 
figure of 10.7%. Thus the percentage is lower 
than the 45% given by some older studies 
further highlighting the technical advances in 
mammography. McDonald et al20 also suggested 
that in some older studies it is not clear if the 
patients examined were asymptomatic. Many 
women request CBE because of breast changes 
they had noted. 
 Shen and Parmigiani21 used decision analysis 
based on a microsimulation model to look at the 
added value, if any, of CBE in combination with 
mammography. Using data from various sources 
such as screening and clinical trials, and focusing 
on women over 40 years of age, they compared 
results in relation to quality adjusted life years 
(QALYs) and cost. They concluded that the most 
cost effective screening was a combination of 
biennial mammography and annual CBE from 
50–79 years of age, but that CBE alone should 
not replace mammography. 
 While there is a low sensitivity (54%) for 
CBE, the specificity is quite high (94%) according 
to Barton et al.4 The figures of the American 
National Breast and Cervical Cancer Early 
Detection Program (NBCCEDP) from 1995–1998 
are comparable: sensitivity 58.8% and specificity 
93.4%.22 Sensitivity is affected by patient 
age, size of tumour, ethnicity, body weight, 
menopausal status and hormone use, varying 
17–88%.22 Experience and training of the clinician 
is also a factor (see below). The high specificity of 
CBE denotes few false positives and this figure 
is higher than that seen with mammography.23 
However, the range for false negatives raises the 
question of what a woman should be told if CBE 
does detect no abnormalities. 
Technique and duration 
The CBE may include inspection and palpation. 
Standard examination textbooks do not give 
evidence for the techniques they describe. A 
1985 study of doctors’ examination techniques 
on silicone breast models found that 40% had 
no discernible pattern of examination.24 Barton 
et al4 recommend an examination sequence 
based on work by Pennypacker et al,24 whose 
research looked at training through the use of 
breast simulators. 
 Clinical breast examination usually starts 
with inspection but the importance of this is 
unproven, particularly in respect to changing 
position and leaning forward.4 A 1982 study 
of a series of 296 breast cancers detected on 
examination found that only 1% was discovered 
by retraction alone and 3% by visible nipple 
abnormalities, leaving 96% discovered only by 
palpation. However, the position of the women 
for inspection is not noted.26 
 While palpation may also be carried out in 
the upright and oblique positions, studies 
suggest that 96% of masses are palpable when 
the patient is supine.27 An interesting variation 
of position was published in a letter from a 
‘country doctor’ in America who describes his 
technique with the patient seated on the edge 
of the examination couch, with her hands on the 
stirrups and leaning forward at a 45° angle so that 
the breast tissue falls away from the chest wall.28 
 Palpation is carried out with the palmar 
surface of the middle three fingers,7,8 although 
Pennypacker recommends using the pads of 
the three middle fingers.25 The breasts are 
examined by feeling the four quadrants of the 
breast7 or are considered as the face of a clock 
and each hour is examined from the outside 
toward the nipple.8 These techniques consider 
the breast as a circular organ whereas other 
clinicians describe it is a rectangle or pentangle, 
an area demarcated by the second and sixth 
ribs, the lateral border of the sternum and the 
mid-axillary line.17 These methods are in contrast 
to Barton et al4 who recommend that palpation 
begins in the axilla and continues in parallel lines 
up and down the breast from the midaxillary 
line to the sternum and down as far as the bra 
line. They call this the ‘vertical strip’ pattern 
or 'lawnmower' technique. Each area of the 
breast is examined by making small circles as 
‘if following the edge of a dime’.4 Only Barton et 
al specify that three pressures are used at each 
spot: light, medium and deep.4 
 Textbooks make no mention of how long a 
breast examination should take. The systematic 
examination recommended by Barton et al 
is said to take at least 3 minutes per side.4 
Saslow et al29 follow the method of Barton et 
al. However, they state that they intentionally 
do not stipulate a duration as the time can 
decrease with increased proficiency, and patient 
factors impact on the examination: quality is 
more important than quantity. 
Factors affecting CBE accuracy
The bigger a breast lump the easier it is to 
detect. Larger lumps are likely to be felt by 
women themselves. Health professionals 
are concerned with detecting small lumps 
or subtle changes occurring in the breasts of 
‘asymptomatic’ women. Studies confirm that 
hard lumps near the surface of the breast are 
more easily palpated than soft, deep lumps, 
although the sensitivities calculated were based 
on the examination of silicone breasts rather 
than patients.30 Tumours smaller than 0.5 cm are 
unlikely to be clinically palpable.31 
 There are differences in the feel of pre- and 
post-menopausal breasts on CBE, with the 
former likely to be denser with a characteristic 
‘lumpiness’; this also affects detection of 
cancer by mammography in younger women. 
Women with lumpy breasts affect the specificity 
of CBE, as more false positive results occur 
in this group.32 It is harder to detect lumps 
in obese women, but CBE is more sensitive 
in Asian women, which may be related to 
their tendency to have smaller breasts than 
caucasian women.33 We would expect that 
clinicians who regularly examine breasts, and 
are able to cope with some uncertainty, are 
more likely to define lumpiness on examination 
as a normal finding and not investigate every 
woman with this characteristic; however, there 
are no papers which specifically discuss this. 
However with models, clinicians have been 
shown to have less detection sensitivity when 
examining the simulation of premenopausal 
breast tissue compared to postmenopausal, 
which raises the question of the usefulness of 
CBE in this population, who are not targeted by 
mammography screening. The highest sensitivity 
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of CBE appears to be in women aged 50–59 
years, ie. those targeted for the mammography 
screening program, while it is lowest in women 
aged 40–49 years.33 As with mammography, 
women who are taking hormone therapy are 
less likely to have breast lumps detected.34
Training
Medical students learn to perform CBE by 
means of clinical teaching associates with 
normal breasts. Further training is required with 
models as these allow students to feel breast 
lumps as small as 3 mm.24 Moreover, once a 
lump has been palpated in facilitated conditions, 
it is more likely that one will be felt in ‘real 
life’. A survey of health professionals providing 
breast checks in Oregon, USA, in 2000, reported 
that 80% were interested in receiving further 
instruction in technique as part of continuing 
professional development.35 
 Silicone breast models are available that 
contain lumps varying in size, hardness and 
depth in tissue. Practising examination on these 
models was shown over 20 years ago to increase 
lump detection rate and that the improved 
skills resulting from such practice translates 
well to examining patients.36 However, many 
smaller lumps will be benign. A more recent 
study involving nurse practitioners showed that 
training with models significantly decreases the 
size of lump detectable on CBE and that nurses 
from all levels of experience benefit from such 
training.37 Training of clinicians may account for 
a 27–29% difference in sensitivity and 14–33% 
difference in specificity according to a 1989 
study which compared the detection rates by 
medical residents with those by women.38
Conclusion
The effect of CBE on mortality from breast 
cancer is still unclear, making it difficult for GPs to 
know exactly what to say to women requesting 
breast examination. Recommendations based 
on this review are given in Table 2. We believe 
that health professionals who do undertake 
CBE of asymptomatic women should participate 
in continuing professional development and 
training to improve their technique and skill. 
They should consider the method they use and 
the time that they take on the examination. 
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